Ketamine Therapy Among Patients With Treatment-resistant Depression: A Randomised, Double-blind, Placebo-controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,069,382.00
Summary
In the last decade, there have been reports of powerful antidepressant effects after a single injection of anaesthetic ketamine, with dramatic (though shortlasting) effects within 24 hours. This will be the first controlled study to test whether a course of repeated ketamine treatments, given over 4 weeks, is effective and safe in treating depression.
Selective Estrogen Receptor Modulators (SERMs) - A Potential New Treatment For Women Of Child-bearing Age With Psychotic Symptoms Of Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$210,480.00
Summary
Schizophrenia is a devastating illness urgently requiring a new treatment approach. We have discovered that estrogen is an effective treatment for women with schizophrenia and are currently trialling a safer Selective Estrogen Receptor Modulator (SERM) known as brain estrogen� in postmenopausal women with schizophrenia. Regulatory permission is now available to trial the SERM in younger women, and we seek to extend our current SERM study into child bearing age women with schizophrenia.
A Selective Prevention Trial Using Novel Pharmacotherapies In An Older Age Cohort At Risk For Depression
Funder
National Health and Medical Research Council
Funding Amount
$975,259.00
Summary
The study will examine whether omega-3 fatty acids or antidepressants prevent the onset of depression in a group of older community participants who have previously been identified as being "at risk" of depression. The study will incorporate sophisticated brain scanning methods, as well as tests of brain functioning to determine acute brain changes, reduction in cognitive decline and prevention of depression over a one-year period.
N-Acetyl Cysteine In Schizophrenia Resistant To Clozapine: A Double-Blind Randomised Placebo-Controlled Trial Targeting Negative Symptoms
Funder
National Health and Medical Research Council
Funding Amount
$981,789.00
Summary
Many patients with schizophrenia remain treatment resistant even after “last resort” medications like clozapine. This proposal will conduct a novel multi-site randomised placebo controlled trial of adjunctive N-acetyl cysteine in patients with clozapine resistant schizophrenia. Treatment efficacy will be examined at 8, 26 and 52 weeks.
Randomised Double-blind Placebo-controlled Study Of Lisdexamfetamine For The Treatment Of Methamphetamine Dependence
Funder
National Health and Medical Research Council
Funding Amount
$1,303,735.00
Summary
Addiction to methamphetamines (‘ice’) is a growing community problem linked to serious disease and death. Current counselling approaches have limited success on their own, and more effective treatments linked to medications are needed. Lisdexamfetamine is a newly licenced stimulant medication with great promise in treating these patients. This trial will examine whether lisdexamfetamine (with counselling) safely reduces methamphetamine use and improves health and wellbeing among heavy users.
A Randomised Controlled Trial To Examine The Effectiveness Of Oxytocin To Improve Treatment For Anorexia Nervosa
Funder
National Health and Medical Research Council
Funding Amount
$415,854.00
Summary
Anorexia nervosa (AN) is a major public health problem. Nutritional rehabilitation programs exist but can be costly and protracted, and patients struggle to engage with these demanding therapies. The purpose of this study is to determine the efficacy of oxytocin nasal spray to improve outcomes in patients with AN participating in a nutritional rehabilitation program using a randomized placebo-controlled design. If shown to be effective, this will have national and international significance.
An RCT Of Cannabinoid Replacement Therapy (Sativex®) For The Management Of Treatment-resistant Cannabis Dependent Patients
Funder
National Health and Medical Research Council
Funding Amount
$788,133.00
Summary
This project is the first-ever outpatient RCT to test if the pharmaceutical cannabinoid Sativex can safely and cost-effectively deliver better treatment outcomes for patients seeking treatment for chronic cannabis dependence. Sativex is a mouth spray with equal parts THC and cannabidiol, and appears to have a safer pharmacological profile than illicit cannabis or synthetic THC alone. Thus Sativex may lead to lower rates of psychiatric adverse events and increased cannabis abstinence rates.
Modifying The Trajectory Of Insidious Late Life Cognitive Decline Using Computerised Cognitive Training
Funder
National Health and Medical Research Council
Funding Amount
$743,152.00
Summary
Supervised, group-based computerised cognitive training (CCT) is a safe and effective intervention to maintain cognition in healthy older adults. This project will examine the extent to which CCT can attenuate or even reverse the rate of decline in older people with previously documented cognitive decline, as well as strategies to maintain CCT effects in the long term.
Plasma protein profiles in normal brain ageing and early stages of dementia. Brain changes related to ageing and dementia are associated with altered proteins that can be detected in the blood. This project will examine blood samples from a number of well-characterised ageing cohorts to discover proteins that may serve as potential markers of brain ageing and the early stages of dementia.